跳到正文
制药经理人· GxP知识岛·· 19 天前同事件AI 评分77

FDA就组分与成品检验缺失向广东邦泽医药发出警告信320-27-10

FDA警告信:广东邦泽医药有限公司

AI 导读

美国FDA于2026年10月26日向广东邦泽医药有限公司发出警告信(编号320-27-10),指其组分与成品检验及质量部门职责存在CGMP违规。信中列出未对原料药和组分做药典鉴别与杂质限度检验、成品放行前COA缺少鉴别和含量数据、质量部门未建立稳定性考察计划等具体条款。

同一件事,精选收录的是《FDA 对 Guangdong Bangze Medicine 发出警告信 320-27-10,指出成分与成品检测等 CGMP 违规》

正文

2026年10月26日,美国FDA向广东邦泽医药有限公司发出警告信(编号320-27-10)。三条违规都指向同一件事:检验数据拿不出来。原料进厂没有药典鉴别和杂质限度检验,成品放行前没有鉴别、含量、杂质数据,质量部门连稳定性考察计划和工艺控制程序都没建立。FDA在结论里建议:请一位符合21 CFR 211.34的合格顾问,做六系统全面审计。原函中英对照如下:

October 26, 2026

2026年10月26日

Reference number: 320-27-10

参考编号:320-27-10

To: Mr. Yongliang Fang, General Manager

收件人:方永亮先生,总经理

Guangdong Bangze Medicine Co., Ltd.

广东邦泽医药有限公司

No. 300 Shangfang Avenue, Simapu Town, Chaonan Qu, Shantou Shi, Guangdong Sheng, 515149, China

中国广东省汕头市潮南区司马浦镇上方大道300号,邮编515149

FDA Establishment Identifier (FEI): 3035364398

FDA企业识别号(FEI):3035364398

Issuing Office: Center for Drug Evaluation and Research (CDER)

发文机构:药品审评与研究中心(CDER)

致方永亮先生:

This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your products and records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.

本警告信告知贵方:美国FDA在审阅贵方产品及贵方设施提交的记录时发现了重大违规,并给予贵方整改机会。请立即处理本函所述违规,不得拖延,包括确保配置充足资源以彻底解决违规并防止再次发生。本函并非贵方设施现有违规的完整清单。确保贵公司符合联邦法律(包括FDA法规)的全部要求,是贵方的责任。未能充分处理违规,可能导致FDA在不另行通知的情况下采取监管措施。

FDA Review

FDA审查

Violations were identified and documented during review of your drug manufacturing facility, Guangdong Bangze Medicine Co., Ltd., FDA Establishment Identifier (FEI) 3035364398. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.

在对贵方药品生产设施——广东邦泽医药有限公司(FDA企业识别号FEI 3035364398)——的审阅中,发现并记录了违规。该审阅是FDA依据法定权限和公共卫生职责开展的,旨在保护公众免受不安全、无效和劣质药品之害。

Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 20, 2026, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.

贵方设施在FDA注册为非处方药(OTC)生产商。针对FDA于2026年1月20日依据《联邦食品、药品和化妆品法案》(FD&C法案)第704(a)(4)条提出的记录及其他信息要求及后续函件,贵方提交了记录,FDA已予审阅。

This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).

本警告信概述了制剂现行药品生产质量管理规范(CGMP)的重大违规。参见《联邦法规汇编》第21编第210、211部分(21 CFR第210、211部分)。

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request, do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).

由于贵方在回复704(a)(4)要求时所描述的生产、加工、包装或贮存药品的方法、设施或控制措施不符合CGMP,贵方药品属于FD&C法案第501(a)(2)(B)条(21 U.S.C. 351(a)(2)(B))意义上的掺假药品。

Violations of the Federal Food, Drug, and Cosmetic Act

违反《联邦食品、药品和化妆品法案》的行为

The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.

以下为本次审阅中发现的违规。再次提醒,本清单并非贵方设施全部违规的完整列表。

1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).

1. 贵公司未对每种组分的样品进行鉴别检验,也未确认其符合有关纯度、含量和质量的全部适当书面规格(21 CFR 211.84(d)(1)与211.84(d)(2))。

Your firm manufactures OTC drug products including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested the identity, purity, or strength of components used in the manufacture of your drug products. You also relied on your suppliers’ certificates of analysis (COA) for (b)(4) without demonstrating the reliability of your suppliers’ test analyses at appropriate intervals.

贵公司生产非处方药,包括(b)(4)。根据贵方提供的记录和信息,贵方未能证明已对药品生产所用组分进行充分的鉴别、纯度或含量检验。贵方还依赖供应商对(b)(4)的分析证书(COA),却未证明在适当间隔对供应商的检验分析进行了可靠性确认。

Your incoming inspection records for your (b)(4) active ingredient failed to include appropriate compendial identity testing, assay, or impurity testing.

贵方对(b)(4)原料药的进厂检验记录未包括适当的药典鉴别检验、含量测定或杂质检测。

You manufacture drugs that contain (b)(4). The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).

贵方生产含(b)(4)的药品。使用被(b)(4)污染的(b)(4),已在全球造成多起人致死性中毒事件。参见FDA指南文件(b)(4)。

Your incoming inspection records for your (b)(4) component similarly failed to include compendial identity testing and lacked appropriate (b)(4) limit testing. Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4).

贵方对(b)(4)组分的进厂检验记录同样未包括药典鉴别检验,也缺少适当的(b)(4)限度检测。(b)(4)及某些其他高风险药品组分的鉴别检验,包括《美国药典》(USP)中的限度检测,以确保该组分符合(b)(4)水平的相关安全限度。

The use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4)

使用被(b)(4)污染的原料,已在全球造成多起人致死性中毒事件。参见FDA指南文件(b)(4)。

Based on the records you provided, you did not perform appropriate (b)(4) testing, including (b)(4) testing, on the (b)(4) used to manufacture your drug products. Your (b)(4) specifications reference the Chinese Pharmacopeia rather than USP for (b)(4). Without adequate (b)(4) testing, you do not have scientific evidence that the (b)(4) used as a component in your drug product manufacturing conforms to appropriate specifications.

根据贵方提供的记录,贵方未对药品生产所用(b)(4)进行适当的(b)(4)检测,包括(b)(4)检测。贵方的(b)(4)规格对(b)(4)引用《中国药典》而非USP。缺乏充分的(b)(4)检测,贵方没有科学证据表明作为组分用于药品生产的(b)(4)符合适当规格。

Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.

组分检验是质量的基础。缺乏充分检验,贵方就没有科学证据表明组分在用于药品生产之前符合适当规格。作为生产商,贵方有责任在生产使用前对药品组分取样、检验和检查,以确保质量充分。

2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).

2. 贵公司未在放行前对每批药品进行适当的实验室检验,以判定其符合药品最终规格(包括各活性成分的鉴别与含量);也未对要求不得检出致病微生物的每批药品,按需要进行适当的实验室检验(21 CFR 211.165(a)与211.165(b))。

Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States. Specifically, the certificate of analyses (COA) that you provided did not include identity, assay, or impurity test results. In addition, the COAs provided also reveal that you lacked appropriate testing for objectionable microorganisms for each batch.

根据贵方提供的记录和信息,贵方未能证明在放行销往美国的非处方药成品之前已进行充分检验。具体而言,贵方提供的分析证书(COA)未包含鉴别、含量测定或杂质检测结果。此外,所提供的COA还显示,贵方未对每批产品进行适当的致病微生物检测。

Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.

检验是CGMP的重要组成部分,用以确保所生产药品符合适合其预期用途的全部既定质量属性。药品在放行和销售前必须对活性成分进行鉴别和含量检验。缺乏充分检验,贵方就没有科学证据确保药品在放行前符合适当规格。

Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).

贵公司质量部门未履行其职责,未能确保所生产药品符合CGMP并满足既定的鉴别、含量、质量和纯度标准(21 CFR 211.22)。

The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure:

贵方提供的记录和信息表明,质量部门(QU)未有效履行监督药品生产质量的职责。例如,贵方质量部门未能确保:

· The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).

· 建立适当且持续的稳定性考察计划(21 CFR 211.166(a))。

· Adequate procedures ensuring appropriate production and process controls, including appropriate qualification of the (b)(4) system (21 CFR 211.100(a)).

· 建立充分的程序以确保适当的生产和工艺控制,包括对(b)(4)系统进行适当确认(21 CFR 211.100(a))。

Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download.

贵公司的质量体系不充分。如需帮助建立质量体系和风险管理方法以满足21 CFR第210、211部分CGMP法规要求,参见FDA指南文件《药品CGMP法规的质量体系方法》:https://www.fda.gov/media/71023/download。

CGMP Consultant Recommended

建议聘请CGMP顾问

Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.

鉴于我们在贵方回复中所发现违规的性质,贵方应聘请符合21 CFR 211.34要求的合格顾问,评估贵方运营并协助贵公司满足CGMP要求。该合格顾问还应对贵方整体运营开展六系统全面审计以评估CGMP合规性,并在贵方寻求解决与FDA的合规状态问题之前,评价纠正和预防措施的完成情况与有效性。

Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

聘请顾问并不免除贵公司遵守CGMP的义务。贵公司管理层仍负有解决所有缺陷和系统性问题的责任,以确保持续符合CGMP。

Conclusion

结论

As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventive measures to ensure future and sustained compliance so that these violations and any others do not occur.

如前所述,贵方有责任调查并确定任何违规的根本原因,实施纠正和预防措施,确保持续合规,使这些违规及其他违规不再发生。

FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 7, 2026.

2026年8月7日,FDA将贵公司拟进口至美国的所有药品和药品制品列入进口警示66-40。

FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.

在任何违规被彻底解决且FDA确认贵方符合CGMP之前,FDA可暂不批准将贵公司列为药品生产商的新申请或补充申请。FDA可能进行检查,以核实贵方已完成针对各项违规的纠正措施。

Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Guangdong Bangze Medicine Co., Ltd., No. 300 Shangfang Avenue, Simapu Town, Chaonan District, Shantou, Guangdong, 515149 China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).

若未处理任何违规,还可能导致FDA依据FD&C法案第801(a)(3)条(21 U.S.C. 381(a)(3)),继续拒绝广东邦泽医药有限公司(中国广东省汕头市潮南区司马浦镇上方大道300号,邮编515149)所生产的产品进入美国。依据该条,疑似掺假的产品可被扣留或拒绝入境,因为其生产所用方法和控制措施似乎不符合FD&C法案第501(a)(2)(B)条(21 U.S.C. 351(a)(2)(B))意义上的CGMP。

Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3035364398 and ATTN: Christopher Jenner in the subject line of the email.

请在收到本函后十五(15)个工作日内,将书面回复发送至CDER-OC-OMQ-Communications@fda.hhs.gov。请在邮件主题中注明FEI 3035364398及收件人ATTN: Christopher Jenner。

If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.

若贵方认为有材料可证明产品未违反FD&C法案及FDA法规,请一并提交供我方考虑。

FDA posts warning letters to www.FDA.gov.

FDA将警告信公布于www.FDA.gov。

Sincerely,

/S/

Francis Godwin

Director

Office of Manufacturing Quality

Office of Compliance

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

此致

(签名)

Francis Godwin

主任

生产质量办公室

合规办公室

药品审评与研究中心

美国食品药品监督管理局

抄送:登记美国代理人;Frosa Technology, LLC;(b)(4)

(译注:文中(b)(4)为FDA依据《信息自由法》第4项豁免所作的脱敏处理。译文仅供学习参考,如与英文原文有歧义,以FDA原文为准。)

来源:制药经理人 · mp.weixin.qq.com

事件后续 · 1

查看事件全部